Allergy and Immunology
Small molecule inhibitors suppress nanoparticle-mediated inflammatory response
Published in Gene Therapy Weekly, March 24th, 2005
"Cancer gene therapy for the treatment of lung cancer has shown promise in the laboratory and in phase I/II clinical trials. However, it is currently limited to treating localized tumors due to host-immunity against the gene delivery vector and the transgene. Therefore, there is a tremendous effort to develop and test alternate gene delivery vectors that are efficient, non-immunogenic, and applicable for systemic therapy," scientists writing in the journal Technology in Cancer Research & Treatment report.
"One such gene delivery vehicle is the non-viral vector,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-03-24)
More Articles from Gene Therapy Weekly
- Gastroenterology
TRAIL gene transfer keeps pancreatic tumors from growing in murine livers - Obstetrics
Adenoviral vectors deliver genes to fetal murine muscle in utero - Oncology
CXCR4 knockdown slows breast tumor growth and invasion - Oncology
Gene silencing sensitizes prostate cancer to cancer therapy - Acute Intracerebral Hemorrhage
Journal publishes results of acute intracerebral hemorrhage study - Addiction Medicine
Cocaine hydrolase gene delivery blunts the heart's response to cocaine - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
